FDA Clears IND for Prime Medicine's PM577a in Wilson Disease, Paving Way for Global Phase 1/2 Trial
PRME sits 15% above its 52-week low of $2.67.
Summary
Prime Medicine received FDA clearance for its IND application for PM577a, a gene editing therapy targeting the H1069Q mutation in Wilson disease. This follows the New Zealand CTA clearance in June, together establishing a global Phase 1/2 program. The company plans to initiate the trial in H2 2026 with initial clinical data expected in 2027. PM577a is the first in vivo Prime Editor to enter the clinic for this indication, representing a significant regulatory de-risking event for the platform. With a market cap around $536M and a cash runway into 2027, advancing the lead program into human studies is a critical value driver. The recent RMAT designation for PM359 and the favorable arbitration outcome against Beam Therapeutics further strengthen the company's position.
At the time of this announcement, PRME was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $536.4M. The 52-week trading range was $2.67 to $6.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.